Tag: Semaglutide

All Podcast Categories
S2-E56 - Day Four at the 2021 TLMdX From AASLD

S2-E56 – Day Four at the 2021 TLMdX From AASLD

Drs. Michael Charlton and Mazen Noureddin and Global Liver Institute Director of Global NASH Programs Jeff McIntyre join Dr. Stephen Harrison, Louise Campbell and Roger Green to review some of the most important and exciting presentations from the final two days of the 2021 TLMdX, the annual meeting of AASLD

S2-E55 - Day Three at the 2021 TLM dX From AASLD

S2-E55 – Day Three at the 2021 TLMdX From AASLD

Profs. Scott Friedman and Michelle Long, Dr. Naim Alkhouri and Global Liver Institute DIrector of Global NASH Programs Jeff McIntyre join Louise Campbell and Roger Green to review some of the most important and exciting presentations from the first three days of the 2021 TLMdX, the annual meeting from AASLD.

S2-E49.2 - Clinical Care Pathway: Behavior Change and Prevalence Data

S2-E49.2 – Clinical Care Pathway: Behavior Change and Prevalence Data

Last author and leading endocrinology Fatty Liver Opinion Leader Ken Cusi joins co-author Stephen Harrison, Louise Campbell and Roger Green to discuss the recent Clinical Care Pathway published in Gastroenterology. This conversation centers on two issues: driving behavior change and recognizing the scope of the need.

S2-E42.3 - Why FGFs Matter - Episode Opening and Closing, Plus a Question About Screen Fail Rates

S2-E42.3 – Why FGFs Matter and Screen Fail Rate

Professor Arun Sanyal and Stephen Harrison provide a 40-minute briefing on fibroblast growth factor (FGFs) agents and why they are so important to the future of NASH and NAFLD therapy. This conversation detours into health policy and screen fail rates before returning to consider the 2-5 year implications of FGF drug therapies.

S2-E41 - Preparing for the NASH Epidemic: Behind a Multidisciplinary Call to Action

S2-E41 – Preparing for the NASH Epidemic: Behind a Multidisciplinary Call to Action

Co-authors Ken Cusi and Stephen Harrison discuss the multidisciplinary call to action regarding the coming NASH Epidemic, how the first paper came to be and what lies behind it, while NASH kNOWledge President Anthony Villiotti, Global Liver Institute Director of Global Policy Andrew Scott and Roger Green share their unique personal perspectives on the need for diverse health professionals to align against Fatty Liver disease.

Stay In Touch with Surfing NASH

Stay In Touch
  • Name
  • Email & NPI
  • Country
  • Institution & Profession